Citi raised the firm’s price target on Argenx (ARGX) to $1,041 from $845 and keeps a Buy rating on the shares. Citi’s neurologist survey indicates that Vyvgart continues to win meaningful market share, the analyst tells investors in a research note. Citi cites Vyvgart growth and increased value for efgartigimod’s pipeline indications for the target increase.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $942 from $887 at BofA
- Argenx’s Vyvgart: Strong Performance and Growth Potential Drive Buy Rating
- Argenx SE Showcases Immunology Innovations at 2025 AANEM Meeting
- Argenx price target raised to $880 from $800 at Wedbush
- Argenx SE Calls Extraordinary Shareholder Meeting for November 2025